Welcome to our dedicated page for Bioatla SEC filings (Ticker: BCAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioAtla, Inc. (BCAB) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context to help interpret them. As a clinical-stage biotechnology company focused on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, BioAtla uses its filings to report on financing arrangements, governance matters, clinical program updates and Nasdaq listing status.
Among the core documents, investors can review Form 8-K current reports where BioAtla describes material events such as Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide equity-linked financing, including key terms like pricing formulas, exchange caps and ownership limits. Other 8-K filings incorporate press releases detailing quarterly financial results and clinical program progress, and discuss interactions with Nasdaq’s Listing Qualifications Staff and conditions for continued listing on The Nasdaq Capital Market.
The DEF 14A definitive proxy statement offers insight into corporate actions submitted to stockholders, including proposals to approve potential issuance of 20% or more of outstanding common stock under financing agreements, authorize a reverse stock split within a specified ratio range at the board’s discretion, and permit adjournments of a special meeting to solicit additional proxies. This proxy statement also explains the rationale for these proposals in the context of Nasdaq Listing Rule 5635(d) and the company’s capital needs.
Through Stock Titan, users can quickly locate BioAtla’s 10-K annual report and 10-Q quarterly reports (when filed) to understand risk factors, detailed financial statements, research and development spending, and discussion of clinical-stage assets such as ozuriftamab vedotin (Oz-V), mecbotamab vedotin (Mec-V), BA3182 and evalstotug. Form 4 insider transaction reports, when available, can be used to track share purchases or sales by directors and officers.
Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections related to financing, listing compliance, and clinical milestones, and surface relevant passages without requiring users to read every page. Real-time updates from EDGAR ensure that new BioAtla filings, including future 8-Ks, proxy materials or registration statements, appear promptly. This combination of primary documents and AI-generated explanations helps investors, analysts and researchers follow how BioAtla’s CAB platform, capital structure and governance are reflected in its SEC reporting.
Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a withholding transaction tied to vested restricted stock units. On 08/31/2025, 2,729 shares were withheld at an effective price of $0.4555 to satisfy income tax and withholding obligations related to prior RSU vesting. After the withholding, the filing shows 364,574 shares beneficially owned by Sievers. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing explicitly states this was a net settlement withholding, not an open-market sale.
Richard A. Waldron, Chief Financial Officer of BioAtla, Inc. (BCAB), reported a transaction dated 08/31/2025 in which 2,371 shares of common stock were disposed of under code F(1) at a price of $0.4555 per share. The filing states these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations related to the vesting and net settlement of previously reported restricted stock units. Following the withholding, the reporting person beneficially owns 338,521 shares (direct ownership). The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/02/2025.
BioAtla, Inc. (Nasdaq: BCAB) filed a Form 8-K covering two routine corporate matters: approval of its 2025 Corporate Bonus Plan and the final results of its 2025 Annual Meeting of Stockholders.
2025 Corporate Bonus Plan (Item 5.02): On 17 June 2025 the Board’s Compensation Committee adopted a cash-based incentive plan for the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer. Payouts are driven by four weighted corporate performance goals—clinical development milestones (25%), financing objectives (50%), financial & people objectives (20%), and brand awareness (5%). A minimum threshold of 50 % aggregate achievement is required for any payout; actual bonuses may range from 50 % to 125 % of the executive’s target opportunity. Target bonuses are set as a percentage of base salary: 60 % for CEO Jay Short and 40 % for both CFO Richard Waldron and CMO Eric Sievers.
Annual Meeting results (Item 5.07): Held virtually on 18 June 2025, the meeting reached a quorum with 30,358,471 shares (≈52 % of shares outstanding) represented. Shareholders re-elected three Class II directors for three-year terms, with Lawrence Steinman, M.D. receiving the highest support (11.6 million votes for). Ernst & Young LLP was ratified as independent auditor for FY 2025 (30.2 million votes for; 99.5 % support). A non-binding “say-on-pay” resolution passed with 8.96 million votes in favor versus 4.49 million against.
No other material transactions, earnings data, or strategic changes were disclosed in this filing.
Form 4 Filing Overview – BioAtla, Inc. (BCAB)
On 18 June 2025, BioAtla filed a Form 4 disclosing that director Susan Moran acquired 23,500 shares of the company’s common stock through a new time-based restricted stock unit (RSU) grant. The award was recorded with transaction code “A” (acquisition) at a deemed price of $0, reflecting an equity compensation grant rather than an open-market purchase.
The RSU vests 100 % on the earlier of 18 June 2026 or the next annual shareholder meeting, contingent on Ms. Moran’s continued board service. Following the grant, her total beneficial ownership rises to 52,307 shares, all held directly.
No derivative securities, sales, or additional transactions were reported. The filing represents routine director compensation and does not involve cash proceeds, option exercises, or insider sales. While it modestly increases insider ownership, it does not provide new information on BioAtla’s operating performance, strategy, or financial outlook.
BioAtla director Eddie Williams received a significant equity grant on June 18, 2025, consisting of 23,500 restricted stock units (RSUs). The RSUs were granted at $0 cost and will fully vest on the earlier of June 18, 2026, or the next annual stockholder meeting, contingent on Williams' continued service.
Following this transaction, Williams' direct beneficial ownership increased to 60,200 shares. The grant represents a standard director compensation arrangement and was reported in compliance with SEC Section 16(a) requirements.
Key details of the RSU grant:
- Time-based vesting structure with one-year cliff
- No exercise price as these are RSUs, not options
- Direct ownership form
- Filed via power of attorney through Christian Vasquez
BioAtla, Inc. (BCAB) – Form 4 insider transaction
Director Lawrence Steinman reported the grant of 23,500 shares of common stock in the form of time-based restricted stock units (RSUs) on 18 June 2025. The RSUs will vest 100% on the earlier of (i) 18 June 2026 or (ii) the next annual meeting of stockholders, conditional upon his continued board service.
- Transaction code: A (award)
- Transaction price: $0 (equity award, not a market purchase)
- Post-transaction direct ownership: 78,459 common shares
No derivative securities were reported. The filing indicates routine board compensation designed to align director incentives with shareholder interests and does not signal any open-market buying or selling by the insider.
Event: On June 18, 2025 BioAtla, Inc. (ticker BCAB) filed a Form 4 disclosing a change in beneficial ownership by director Mary Ann Gray.
Key Details
- Securities granted: 23,500 shares of common stock issued as a time-based restricted stock unit (RSU) award.
- Transaction price: $0, reflecting that the RSU grant was part of equity compensation rather than an open-market purchase.
- Vesting schedule: 100 % of the RSUs will vest on the earlier of (i) June 18, 2026 or (ii) the company’s next annual meeting of stockholders, subject to continued board service.
- Post-transaction holdings: After the grant, Gray’s direct ownership stands at 77,397 shares.
The filing does not report any sales, option exercises, or derivative securities activity beyond this RSU grant. No 10b5-1 trading plan is referenced for the transaction.
Investor context: A single director-level RSU grant of 23.5k shares is routine board compensation and represents roughly 0.06 % of BioAtla’s ~39 million shares outstanding. While it marginally aligns the director’s incentives with shareholders, it is unlikely to have a material impact on valuation, liquidity, or control dynamics.
BioAtla Director Sylvia McBrinn received a grant of 23,500 restricted stock units (RSUs) on June 18, 2025. Following this transaction, McBrinn's total direct beneficial ownership increased to 59,125 shares of common stock.
Key details of the RSU grant:
- The RSUs were granted at $0 exercise price
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service through the vesting date
This Form 4 filing indicates standard equity-based compensation for a board member, which aligns the director's interests with shareholders. The transaction was executed pursuant to the company's director compensation program and represents a significant addition to McBrinn's equity stake in BioAtla.